Patents by Inventor David Wassarman

David Wassarman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10207011
    Abstract: Described herein are methods, systems, and devices for identifying agents and genetic pathways that modulate the effects of traumatic brain injury (TBI) in invertebrate model systems having a brain, e.g., Drosophila or C. elegans.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: February 19, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Barry S. Ganetzky, David A. Wassarman
  • Publication number: 20140377183
    Abstract: Described herein are methods, systems, and devices for identifying agents and genetic pathways that modulate the effects of traumatic brain injury (TBI) in invertebrate model systems having a brain, e.g., Drosophila or C. elegans.
    Type: Application
    Filed: June 25, 2014
    Publication date: December 25, 2014
    Inventors: Barry S. Ganetzky, David A. Wassarman
  • Publication number: 20060128660
    Abstract: The present invention provides FK228 analogs and methods of making and using the same. Such analogs are potent inhibitors of histone deacetylase and, in certain embodiments, are capable of specifically targeting cancerous cells and tissues. In preferred embodiments, these analogs are characterized by a cyclic disulfide design.
    Type: Application
    Filed: December 10, 2004
    Publication date: June 15, 2006
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Scott Rajski, David Wassarman, Jose Restituyo
  • Publication number: 20060115482
    Abstract: The invention provides a method of a method of characterizing the proliferative state of cells in a biological sample based on detecting transcription factor-mediated phosphorylation of histone H2B (H2B) at residue 36 (numbered according to human H2B). This method optionally includes detection of transcription factor-mediated acetylation of histone H3 (H3) at residue 14 and/or acetylation of histone H4, which also provides an indication of cell proliferation. The invention also provides antibodies specific for H2B phosphorylated at H2B; transcription factor and H2B derivatives and related polynucleotides, vectors, host cells, recombinant production methods and compositions; and screening methods for modulators of H2B phosphorylation at residue 36.
    Type: Application
    Filed: April 26, 2005
    Publication date: June 1, 2006
    Inventors: Frank Sauer, David Wassarman, Tobias Maile
  • Patent number: 5747288
    Abstract: The kinase suppressor of Ras (Ksr), a novel protein kinase involved in the regulation of cell growth and differentiation, provides an important target for therapeutic intervention. The subject compositions also include nucleic acids which encode a Ksr kinase, and hybridization probes and primers capable of hybridizing with a Ksr gene. Such probes are used to identify mutant Ksr alleles associated with disease. The invention includes methods, including phosphorylation and binding assays, for screening chemical libraries for lead compounds for a pharmacological agent useful in the diagnosis or treatment of disease associated Ksr activity or Ksr-dependent signal transduction.
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: May 5, 1998
    Assignee: The Regents of the University of California
    Inventors: Gerry Rubin, Marc Therrien, Henry Chang, Felix Karim, David Wassarman
  • Patent number: 5747275
    Abstract: The kinase suppressor of Ras (Ksr), a novel protein kinase involved in the regulation of cell growth and differentiation, provides an important target for therapeutic intervention. The subject compositions also include nucleic acids which encode a Ksr kinase, and hybridization probes and primers capable of hybridizing with a Ksr gene. Such probes are used to identify mutant Ksr alleles associated with disease. The invention includes methods, including phosphorylation and binding assays, for screening chemical libraries for lead compounds for a pharmacological agent useful in the diagnosis or treatment of disease associated Ksr activity or Ksr-dependent signal transduction.
    Type: Grant
    Filed: August 12, 1997
    Date of Patent: May 5, 1998
    Assignee: The Regents of the University of California
    Inventors: Gerry Rubin, Marc Therrien, Henry Chang, Felix Karim, David Wassarman
  • Patent number: 5700675
    Abstract: The kinase suppressor of Ras (Ksr), a novel protein kinase involved in the regulation of cell growth and differentiation, provides an important target for therapeutic intervention. The subject compositions also include nucleic acids which encode a Ksr kinase, and hybridization probes and primers capable of hybridizing with a Ksr gene. Such probes are used to identify mutant Ksr alleles associated with disease. The invention includes methods, including phosphorylation and binding assays, for screening chemical libraries for lead compounds for a pharmacological agent useful in the diagnosis or treatment of disease associated Ksr activity or Ksr-dependent signal transduction.
    Type: Grant
    Filed: December 13, 1995
    Date of Patent: December 23, 1997
    Assignee: Regents of the University of California
    Inventors: Gerry Rubin, Marc Therrien, Henry Chang, Felix Karim, David Wassarman